Xarelto Litigation May be Consolidated as MDL

Xarelto (rivaroxoaban) is an anticoagulant designed and manufactured by Janssen Pharmaceuticals, a Bayer and Johnson & Johnson subsidiary. While it was intended to reduce the risk of stroke among patients with atrial fibrillation and was intended to provide a safe, effective alternative to warfarin, growing numbers of patients across the country have filed Xarelto lawsuits, claiming that the drug has led to significant bleeding injuries and death.

Although a product liability lawsuit may help some families recoup their costs, it may take years before they’ll see a dime from the litigation. In the meantime, those who have filed Xarelto lawsuits may seek advance funding in the form of a pre settlement loan.

Motion for MDL formation

At least 21 Xarelto lawsuits have been filed in federal courts across the country. Recently, a motion for transfer was filed by a group of these plaintiffs. The plaintiffs have requested that the U.S. Panel on Multidistrict Litigation (JPML) consolidate the federal cases and move them to the U.S. District Court for the Southern District of Illinois. If the motion is granted, the newly formed multidistrict litigation (MDL) would be overseen by Judge David R. Herndon.

The formation of multidistrict litigations is a common event when large numbers of plaintiffs file lawsuits against a common defendant regarding similar allegations and statements of fact. Consolidating the cases for the purposes of pre-trial discovery can streamline the litigation process and save costs for all parties. Additionally, it prevents the possibility of contradicting rulings and duplicative discovery. After discovery and following the resolution of the first few cases, known as bellwether trials, the remaining cases that have not reached a settlement agreement will be remanded back for trial in their home districts.

Litigation is a lengthy process

Even though the formation of an MDL would streamline the litigation process, it is still likely to take months if not years before the first few cases would go to trial. In the meantime, Xarelto plaintiffs may be tempted to settle their cases for less money than they deserve because their bills are piling up. Plaintiffs who file product liability lawsuits with regard to dangerous medications are often faced with significant medical expenses, surgical costs, pharmaceutical expenses, and rehabilitation needs, in addition to everyday living expenses such as mortgage payments and insurance premiums.

For many of these individuals, Xarelto pre settlement funding may be the right step to keep themselves afloat. Unlike a traditional bank loan or line of credit, a Xarelto lawsuit cash advance is non-recourse. In the event that the plaintiff loses the case, the money never needs to be repaid. There is absolutely no risk for the plaintiff. Plus, the cash advance can be used for anything the plaintiff needs – from legal fees to groceries – with no restrictions.

Apply for Xarelto lawsuit advance funding

Have you suffered a significant bleeding event after using Xarelto? Have you lost a loved one to uncontrollable bleeding? If you’ve filed a lawsuit against the manufacturer, you could be eligible to receive Xarelto lawsuit advance funding from LawStreet Capital. As one of the leading lawsuit funding companies in the industry, LawStreet Capital prides itself on consumer transparency.

There are never any hidden fees and no risk for the plaintiff. We offer fast approval and rapid payments to help cash-strapped plaintiffs. Simply fill out the online form or call a friendly representative at 888-566-1189.